Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 416970 in Healthy Volunteers
NCT02093819Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of CNTX-6970 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events. Started Apr 2014; status: completed.
02
Drugs
CNTX-6970
Beyond the preview
Go deeper on NCT02093819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093819.